Konstantinos Zormpas-Petridis

Konstantinos Zormpas-Petridis

Auto-generated profile, based on publicly available information

Konstantinos Zormpas-Petridis

Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 November 2019 in Cancer Research
Verified
Journal Article
Open access
PDF file
JLJin Li
Jin Li
KZKonstantinos Zormpas-Petridis
Konstantinos Zormpas-Petridis
JBJessica K.R. Boult
Jessica K.R. Boult
EREmma L. Reeves
Emma L. Reeves
AHAndreas Heindl
Andreas Heindl
SRSimon P. Robinson
Simon P. Robinson
Increased stiffness in the extracellular matrix (ECM) contributes to tumor progression and metastasis. Therefore, stromal modulating therapies and accompanying biomarkers are being developed to target ECM stiffness. Magnetic resonance (MR) elastography can noninvasively and quantitatively map the viscoelastic properties of tumors in vivo and thus has clear clinical applications. Herein, we used MR elastography, coupled with computational histopathology, to interrogate the contribution of collagen to the tumor biomechanical phenotype and to evaluate its sensitivity to collagenase-induced stromal modulation. Elasticity (Gd) and viscosity (Gl) were significantly greater for orthotopic BT-474 (Gd = 5.9 ± 0.2 kPa, Gl = 4.7 ± 0.2 kPa, n = 7) and luc-MDA-MB-231-LM2-4 (Gd = 7.9 ± 0.4 kPa, Gl = 6.0 ± 0.2 kPa, n = 6) breast cancer xenografts, and luc-PANC1 (Gd = 6.9 ± 0.3 kPa, Gl = 6.2 ± 0.2 kPa, n = 7) pancreatic cancer xenografts, compared with tumors associated with the nervous system, including GTML/Trp53KI/KI medulloblastoma (Gd = 3.5 ± 0.2 kPa, Gl = 2.3 ± 0.2 kPa, n = 7), orthotopic luc-D-212-MG (Gd = 3.5 ± 0.2 kPa, Gl = 2.3 ± 0.2 kPa, n = 7), luc-RG2 (Gd = 3.5 ± 0.2 kPa, Gl = 2.3 ± 0.2 kPa, n = 5), and luc-U-87-MG (Gd = 3.5 ± 0.2 kPa, Gl = 2.3 ± 0.2 kPa, n = 8) glioblastoma xenografts, intracranially propagated luc-MDA-MB-231-LM2-4 (Gd = 3.7 ± 0.2 kPa, Gl = 2.2 ± 0.1 kPa, n = 7) breast cancer xenografts, and Th-MYCN neuroblastomas (Gd = 3.5 ± 0.2 kPa, Gl = 2.3 ± 0.2 kPa, n = 5). Positive correlations between both elasticity (r = 0.72, P < 0.0001) and viscosity (r = 0.78, P < 0.0001) were determined with collagen fraction, but not with cellular or vascular density. Treatment with collagenase significantly reduced Gd (P = 0.002) and Gl (P = 0.0006) in orthotopic breast tumors. Texture analysis of extracted images of picrosirius red staining revealed significant negative correlations of entropy with Gd (r = −0.69, P < 0.0001) and Gl (r = −0.76, P < 0.0001), and positive correlations of fractal dimension with Gd (r = 0.75, P < 0.0001) and Gl (r = 0.78, P < 0.0001). MR elastography can thus provide sensitive imaging biomarkers of tumor collagen deposition and its therapeutic modulation.Significance: MR elastography enables noninvasive detection of tumor stiffness and will aid in the development of ECM-targeting therapies.

1 September 2021 in Radiology: Artificial Intelligence
Verified
Journal Article
Open access
KZKonstantinos Zormpas-Petridis
Konstantinos Zormpas-Petridis
NTNina Tunariu
Nina Tunariu
ACAndra Curcean
Andra Curcean
CMChristina Messiou
Christina Messiou
SCSebastian Curcean
Sebastian Curcean
MBMatthew Blackledge
Matthew Blackledge
A developed model, called quickDWI, enabled accelerated acquisition protocols for whole-body diffusion-weighted MRI of metastatic prostate, breast, and myeloma bone disease by using deep learning, ... Purpose To use deep learning to improve the image quality of subsampled images (number of acquisitions = 1 [NOA1]) to reduce whole-body diffusion-weighted MRI (WBDWI) acquisition times. Materials a...

14 August 2020 in Cancer Research
Verified
Journal Article
Open access
PDF file
KZKonstantinos Zormpas-Petridis
Konstantinos Zormpas-Petridis
EPEvon Poon
Evon Poon
MCMatthew Clarke
Matthew Clarke
NJNeil P. Jerome
Neil P. Jerome
JBJessica K. R. Boult
Jessica K. R. Boult
YJYann Jamin
Yann Jamin
Noninvasive early indicators of treatment response are crucial to the successful delivery of precision medicine in children with cancer. Neuroblastoma is a common solid tumor of young children that arises from anomalies in neural crest development. Therapeutic approaches aiming to destabilize MYCN protein, such as small-molecule inhibitors of Aurora A and mTOR, are currently being evaluated in early phase clinical trials in children with high-risk MYCN-driven disease, with limited ability to evaluate conventional pharmacodynamic biomarkers of response. T1 mapping is an MRI scan that measures the proton spin-lattice relaxation time T1. Using a multiparametric MRI-pathologic cross-correlative approach and computational pathology methodologies including a machine learning–based algorithm for the automatic detection and classification of neuroblasts, we show here that T1 mapping is sensitive to the rich histopathologic heterogeneity of neuroblastoma in the Th-MYCN transgenic model. Regions with high native T1 corresponded to regions dense in proliferative undifferentiated neuroblasts, whereas regions characterized by low T1 were rich in apoptotic or differentiating neuroblasts. Reductions in tumor-native T1 represented a sensitive biomarker of response to treatment-induced apoptosis with two MYCN-targeted small-molecule inhibitors, Aurora A kinase inhibitor alisertib (MLN8237) and mTOR inhibitor vistusertib (AZD2014). Overall, we demonstrate the potential of T1 mapping, a scan readily available on most clinical MRI scanners, to assess response to therapy and guide clinical trials for children with neuroblastoma. The study reinforces the potential role of MRI-based functional imaging in delivering precision medicine to children with neuroblastoma. Significance: This study shows that MRI-based functional imaging can detect apoptotic responses to MYCN-targeted small-molecule inhibitors in a genetically engineered murine model of MYCN-driven neuroblastoma.

13 September 2022 in Computers in Biology and Medicine
Verified
Journal Article
Open access
KZKonstantinos Zormpas-Petridis
Konstantinos Zormpas-Petridis
NTNina Tunariu
Nina Tunariu
DCDavid J. Collins
David J. Collins
CMChristina Messiou
Christina Messiou
DKDow-Mu Koh
Dow-Mu Koh
MBMatthew Blackledge
Matthew Blackledge
Purpose: To use deep learning to calculate the uncertainty in apparent diffusion coefficient (uADC) voxel-wise measurements to clinically impact the monitoring of treatment response and improve the quality of ADC maps. Materials and methods: We use a uniquely designed diffusion-weighted imaging (DWI) acquisition protocol that provides gold-standard measurements of uADC to train a deep learning model on two separate cohorts: 16 patients with prostate cancer and 28 patients with mesothelioma. Our network was trained with a novel cost function, which incorporates a perception metric and a b-value regularisation term, on ADC maps calculated by combinations of 2 or 3 b-values (e.g. 50/600/900, 50/900, 50/600, 600/900 s/mm(2)). We compare the accuracy of the deep-learning based approach for estimation of uADC with gold-standard measurements. Results: The model accurately predicted the uADC for every b-value combination in both cohorts. Mean values of uADC within areas of active disease deviated from those measured by the gold-standard by 4.3% (range, 2.87-6.13%) for the prostate and 3.7% (range, 3.06-4.54%) for the mesothelioma cohort. We also showed that the model can easily be adapted for a different DWI protocol and field-of-view with only a few images (as little as a single patient) using transfer learning. Conclusion: Deep learning produces maps of uADC from standard clinical diffusion-weighted images (DWI) when 2 or more b-values are available.

13 March 2026 in Critical Reviews in Oncology/Hematology
Verified
Journal Article
Open access
MCMaria Chiara Cannizzaro
Maria Chiara Cannizzaro
AMAngelo Minucci
Angelo Minucci
KZKonstantinos Zormpas-Petridis
Konstantinos Zormpas-Petridis
VGViola Ghizzoni
Viola Ghizzoni
AFANNA FAGOTTI
ANNA FAGOTTI
CNcamilla nero
camilla nero
Homologous recombination deficiency (HRD) plays a central role in the pathogenesis and therapeutic vulnerability of epithelial ovarian cancer (EOC), particularly in high-grade serous subtypes. HRD reflects the inability of tumor cells to accurately repair DNA double-strand breaks, rendering them sensitive to platinum-based chemotherapy and poly(ADP-ribose) polymerase (PARP) inhibitors. Several genomic assays have been developed to identify HRD status through the detection of genomic instability patterns, with varying degrees of clinical validation and regulatory approval. Beyond widely adopted assays such as Myriad myChoice® CDx and FoundationFocus™ CDx BRCA LOH, innovative approaches including the Leuven PARPi Benefit Test, circulating tumor DNA-based methods, and artificial intelligence-driven computational pathology are reshaping the diagnostic landscape. Nevertheless, important challenges remain, including the static nature of genomic scar assays, the impact of tumor heterogeneity, and the emergence of resistance through reversion mutations. Functional assays and integrative strategies may provide more dynamic insights into real-time DNA repair capacity, thereby supporting more accurate patient selection and treatment monitoring. Cost-effectiveness analyses further support the integration of HRD testing at diagnosis, highlighting its role in guiding optimal use of PARP inhibitors and improving healthcare resource allocation. This review summarizes the biological rationale, diagnostic methods, therapeutic implications, and economic considerations of HRD in EOC, with a focus on first-line maintenance strategies and future directions in precision oncology.

16 March 2026 in European Radiology Experimental
Verified
Journal Article
Open access
PDF file
KZKonstantinos Zormpas-Petridis
Konstantinos Zormpas-Petridis
RKReza Kalantar
Reza Kalantar
LILudovica Iaccarino
Ludovica Iaccarino
MMMatteo Mancino
Matteo Mancino
GFGianluca Franceschini
Gianluca Franceschini
ADAnna D’ANgelo
Anna D’ANgelo
Objective: We used deep learning to generate synthetic, resembling in appearance, iodine-enhanced, mammograms from low-energy contrast-enhanced mammography (CEM) images. Materials and methods: We retrospectively selected 140 CEM examinations. We trained a two-dimensional cycle-generative adversarial network on 390 images in 100 patients (195 breasts; 102 positive and 93 negative for lesion detection) using paired low-energy and iodine-enhanced images as input and output, respectively. We validated our model in 40 test patients (63 breasts; 37 positive and 26 negative for lesion detection) by calculating the contrast-to-noise ratio (CNR) for low-energy, synthetic, and clinical iodine-enhanced images and the mean absolute error (MAE) and similarity index metric (SSIM) between clinical and synthetic iodine-enhanced images regarding their changes from low-energy. Three radiologists scored (a-to-d) the test set images for background parenchymal enhancement (BPE) and lesion detection (yes/no) on clinical and synthetic images. The presence of artifacts was reported on all images. Results: We observed a high correlation between clinical and synthetic iodine-enhanced images regarding their changes from low-energy: MAE, r = 0.99; SSIM, r = 0.80. CNR was -0.015/-0.16 ± 0.23/0.05 (mean ± standard deviation) for clinical/synthetic, respectively. A “halo” artifact present in above 50% of the clinical iodine-enhanced images was corrected in the synthetic ones. On synthetic images, BPE (scores a–b versus c–d) was 85.8% accurate. Lesion detection accuracy was 89.4% and 79.4%, sensitivity 87.4 and 72.1%, and specificity 92.3% and 90.0% for clinical and synthetic images, respectively. Conclusions: Deep learning holds the potential to generate synthetic iodine-enhanced mammograms from low-energy images. Relevance statement: Radiologists could perform some clinical tasks, such as lesion detection and BPE estimation on synthetic iodine-enhanced images, without contrast injection. Key Points: Our deep learning model generated synthetic iodine-enhanced images that visually resembled the clinical iodine-enhanced images. Radiologists could use the synthetic images to perform clinical tasks, such as lesion detection and BPE evaluation. Our model can improve image quality by removing common artifacts, including the breast-in-breast (halo). Our method is a way to combine the benefits of CEM while sparing the need for contrast media. Graphical